Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
One of the best tools to help practitioners make the best bedside clinical decisions when managing patients with acute cardiovascular disease.
A comprehensive guidelines implementation toolkit especially for Nurses & Allied Professionals.
Prof. Josef Niebauer
Prof. Paul Dendale ,
Discover general recommendations on the management of diabetes mellitus.
ESC and European Association for the Study of Diabetes scientific statements (Ryden L 2013) as well as the most recent ESC Prevention Guideline (Piepoli MF 2016) call on page 2355 for lifestyle management as a first line intervention for the prevention and treatment of diabetes mellitus type 2 (DMT2).
Imagine a medical treatment with similar proven efficacy that is withheld! Patients and doctors together should urge politicians and health insurance companies to have a sufficient number of programmes implemented. The costs should be covered by the insurance companies, like any other medical therapy of comparable class and level of proven efficacy.
Further “Recommendations on the management of diabetes” are given in the following table (Piepoli MF, Eur Heart 2016):
BP: blood pressure; CV: cardiovascular; DM: diabetes melitus; HbAc: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; SGLT2: Sodium-glucose co-transporter-2.
aClass of recommendation.
bLevel of evidence
cReference(s) supporting recommendations.
dNon-HDL-C is a reasonable and practical alternative target because it does not require fasting. Non HDL-C secondary targets of
Access the European Guidelines on CVD Prevention in Clinical Practice.
Piepoli MF et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016;37:2315–2381.
Ryden L et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035–3087.
The ESC Prevention of Cardiovascular Disease programme is supported by AMGEN, AstraZeneca, Ferrer, and Sanofi and Regeneron in the form of educational grants.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.